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Abstract
RNA polymerase II mediates the transcription of all protein-coding genes in eukaryotic cells, a 
process that is fundamental to life. Genomic mutations altering this enzyme have not previously 
been linked to any pathology in humans, which is a testament to its indispensable role in cell 
biology. On the basis of a combination of next-generation genomic analyses of 775 meningiomas, 
we report that recurrent somatic p.Gln403Lys or p.Leu438_His439del mutations in POLR2A, 
which encodes the catalytic subunit of RNA polymerase II (ref. 1), hijack this essential enzyme 
and drive neoplasia. POLR2A mutant tumors show dysregulation of key meningeal identity 
genes2, 3, including WNT6 and ZIC1/ZIC4. In addition to mutations in POLR2A, NF2, 
SMARCB1, TRAF7, KLF4, AKT1, PIK3CA, and SMO4, 5, 6, 7, 8, we also report somatic 
mutations in AKT3, PIK3R1, PRKAR1A, and SUFU in meningiomas. Our results identify a role 
for essential transcriptional machinery in driving tumorigenesis and define mutually exclusive 
meningioma subgroups with distinct clinical and pathological features.
Transcriptional regulation is a precisely orchestrated process that involves a diverse 
collection of molecules ranging from large-scale chromatin remodelers to gene-specific 
modifiers. Alterations in components of transcriptional regulation are particularly prevalent 
in neoplasia; such alterations include histone H3 mutations in pediatric glioblastoma9, 
mediator subunit mutations in uterine leiomyosarcoma10, and mutations of specific 
transcription factors in multiple cancer types11. Transcriptional machinery cooperatively acts 
to attract the multimeric enzyme RNA polymerase II (Pol II) to selective genomic sites, 
ultimately driving transcription of all mRNAs and most micro- and small nuclear RNAs. In 
this capacity, Pol II coordinates virtually every component of eukaryotic transcription, from 
pre-initiation to splicing and other post-transcriptional modifications. Loss of Pol II activity 
is incompatible with life, such that the ingestion of the potent Pol II inhibitorα-amanitin is 
fatal12. Given the essential biological functions of Pol II, it is not surprising that no 
mutations affecting any of its components have ever been reported in human disease.
Meningiomas, which arise from the membranes surrounding the brain and spinal cord, are 
the most common intracranial tumors13. We and others have previously identified somatic 
mutations in seven genes (NF2 with co-occurring mutations in SMARCB1, TRAF7 with a 
recurrent mutation in KLF4 or mutations affecting PI3K signaling through AKT1 or 
PIK3CA mutations, and SMO) and/or loss of chromosome 22 (chr22) to define mutually 
exclusive subgroups4, 5, 6, 7, 8. To discover the genetic basis of the remaining mutation-
unknown tumors, we used iterative, integrated genomic approaches on a set of 775 
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meningiomas, including 485 primary, previously unradiated grade I tumors (Supplementary 
Table 1).
Focusing on samples that lacked known meningioma driver genes, we discovered recurrent 
mutations in POLR2A (polymerase (RNA) II (DNA directed) polypeptide A, 220 kDa), 
which encodes RPB1, the largest and catalytic subunit of Pol II. Recurrent POLR2A 
p.Gln403Lys (n = 19) or p.Leu438_His439del (n = 4) mutations accounted for 
approximately 6% of all benign cases. POLR2A mutations affected exon 7 and localized 
near each other in the highly conserved dock domain, which mediates interactions between 
Pol II and TFIIB during formation of the pre-initiation complex (Fig. 1a,b). These 
alterations were confirmed as somatic in all samples with available blood pairing and were 
mutually exclusive with previously established drivers4 (P = 3.02 × 10−10, one-sided 
Fisher’s exact test) (Fig. 1c,d). Whole-genome sequencing of three POLR2A meningioma–
blood pairs did not identify recurrent chromosomal translocations (Fig. 1e, Supplementary 
Fig. 1, and Supplementary Table 2). Indeed, similar to other benign meningiomas, most 
POLR2A mutant tumors (88.2%) were genomically stable without detectable large-scale 
chromosomal amplifications or deletions (average percentage of the genome altered: 1.2%, 
4.7%, and 0.6% in POLR2A, NF2, and non-NF2 mutant meningiomas, respectively) (Fig. 1f 
and Supplementary Table 1).
POLR2A mutant meningiomas had a small number of rare, protein-altering somatic 
mutations (mean, 0.17 per Mb of sequencing; range, 0.03–0.30); this number was not 
significantly different from that in tumors harboring mutations in established meningioma 
genes (mean, 0.23 per Mb of sequencing; P = 0.08, POLR2A versus others for deleterious 
somatic mutations; P = 0.82 for all somatic mutations; two-sided Student’s t-test) (Fig. 1g, 
Supplementary Table 3, and Supplementary Fig. 2). Furthermore, POLR2A mutations and 
mutations in other meningioma driver genes were found to be mutually exclusive, and no 
additional genes were found to be co-mutant in more than two exome-sequenced POLR2A-
mutant samples (Supplementary Tables 1 and 3). Clinically, POLR2A-mutant tumors 
harbored distinct characteristics, including meningothelial histology (P = 3.62 × 10−4, 
Fisher’s exact test) and a tendency to originate from the tuberculum sellae region (P = 1.51 × 
10−5, Fisher’s exact test), where the pituitary gland is located (Fig. 1h and Supplementary 
Table 4). POLR2A mutations were exclusively detected in WHO grade I (benign) 
meningiomas, with no events found in 159 grade II or grade III (atypical or malignant) 
meningiomas screened for these variants. The homogeneous clinical features and genomic 
stability of this group suggests that recurrent POLR2A mutations classify a unique subset of 
benign, but not atypical or malignant, meningiomas.
Among the remaining mutation-unknown samples in our cohort, we also identified somatic 
alterations in several other genes whose role in meningioma was not fully appreciated. 
Among NF2-mutant meningiomas, we found that a surprisingly large number of samples 
(6.4%) harbored recurrent p.Arg383Gln or p.Arg386His missense mutations affecting 
SMARCB1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily B member 1) (n = 2 or 14, respectively, out of 250 NF2-mutant meningiomas 
screened). Although our group and others have noted somatic alterations in SMARCB1 in 
meningiomas4, 7, their recurrent nature, frequency, and co-occurrence with somatic NF2 
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mutations were not previously appreciated. Interestingly, most of the NF2/SMARCB1 
mutant samples originated from the midline dura (falx) of the anterior convexity 
(Supplementary Tables 1 and 5), a region in which NF2 tumors lacking SMARCB1 
mutations are rarely found (70% versus 16%, respectively; P = 1.75 × 10−4, two-sided 
Fisher’s exact test; odds ratio = 13.08; 95% confidence interval = 2.83–83.09 for 
SMARCB1/NF2 versus NF2 localizing to anterior falx).
In the TRAF7 meningioma subgroup, we identified an intronic hot spot that harbored 
somatic mutations affecting the interval just upstream of the first WD40 repeat domain (n = 
12) (Fig. 2a,b). Mutations in this region alter the splicing of exons 10 and 11, and result in 
the inclusion of a 28-amino-acid in-frame insertion and a Ser-to-Cys missense mutation 
(Fig. 2c and Supplementary Fig. 3). We also discovered co-mutations occurring with TRAF7 
that activate PI3K signaling, including somatic hot-spot mutations in PIK3CA (PI3K 
catalytic subunit, alpha) that were previously noted by our group and others4, 8 (Fig. 2d), in 
PIK3R1 (PI3K regulatory subunit, alpha), and in AKT3 (v-akt murine thymoma viral 
oncogene homolog 3). The somatic AKT3 p.Glu17Lys variant observed in one whole-
exome-sequenced meningioma was previously characterized to activate AKT signaling in 
melanoma14 (Supplementary Table 1). These mutations were mutually exclusive with each 
other and also with the previously described AKT1 p.Glu17Lys recurrent mutation. Overall, 
among primary and benign meningiomas, which localized primarily to the anterior skull 
base or convexity regions and were screened for mutations in PIK3CA, mutations in 
PIK3R1, and the recurrent AKT1 p.Glu17Lys variant (n = 333), we identified PI3K pathway 
mutations in 19.22% of tumors (n = 64; 42 with AKT1 p.Glu17Lys mutations, 20 with 
PIK3CA, and 2 with PIK3R1) (Supplementary Table 1).
We also identified new alterations in genes associated with Sonic hedgehog (SHH) 
signaling, including loss-of-function mutations in SUFU (suppressor of fused homolog 
(Drosophila)) (n = 5) and a recurrent p.Ala17Asp missense mutation in PRKAR1A (protein 
kinase, CAMP-dependent, regulatory, type I, alpha) (n = 3) (Supplementary Fig. 4). SUFU is 
a known tumor suppressor gene and acts downstream of SMO to inhibit SHH signaling. A 
germline SUFU mutation (p.Arg123Cys) with somatic loss of the wild-type allele has 
previously been described in a family with multiple meningiomas15, but somatic SUFU 
mutations have not been reported in sporadic meningiomas. Similarly, PRKAR1A mutations 
have not previously been reported in meningiomas but have been identified in multiple 
neoplasia syndrome Carney complex16. Inactivation of PRKAR1A has been shown to result 
in constitutive PKA activation, with ultimate effects on the balance of SHH signaling17.
Somatic mutations in NF2, TRAF7 (co-occurring with either the KLF4 p.Lys409Gln or 
PI3K pathway mutations), genes in the Hedgehog pathway, and POLR2A were all mutually 
exclusive, defining distinct meningioma subgroups (Fig. 2e). With these subtypes identified 
(Fig. 2f), we next aimed to gain insight into the mechanisms by which these driver genes 
lead to the formation of meningiomas. We initially focused on POLR2A mutant tumors. The 
Pol II holoenzyme mediates multiple essential cellular processes, such that mutations 
affecting its subunits can potentially drive neoplasia through a range of biological 
mechanisms. The dock domain of RPB1 is necessary for bridging among Pol II, TFIIB, and 
TFIID (which contains the TATA-box binding protein) during transcription initiation. The 
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fidelity of this interaction ensures that Pol II’s catalytic subunit is correctly positioned at the 
DNA promoter, and defects could conceivably affect splicing, transcript accuracy, DNA 
repair, gene expression, or other essential processes. RNA sequencing of POLR2A 
meningiomas did not identify significant changes in splicing, differential promoter usage, or 
transcription errors (Supplementary Tables 6 and 7 and Supplementary Fig. 2). We also did 
not identify a significant difference in the total number of somatic coding and noncoding 
mutations between POLR2A-mutant tumors and others (P = 0.82; Fig. 1f and 
Supplementary Fig. 2), suggesting that defects in DNA repair are unlikely to underlie these 
tumors. We next used CRISPR–Cas9 gene editing to create knock-in models of the two 
POLR2A dock domain mutations in mouse embryonic stem cells and again did not identify 
any significant difference in splicing or differential promoter use (Supplementary Tables 8 
and 9) or any evidence supporting global transcriptional amplification18 (Supplementary 
Fig. 5).
We next carried out expression profiling across a large cohort of meningiomas (n = 79). We 
identified distinct clusters that were almost completely consistent with our established 
subgroups, suggesting that the transcriptional architecture of each tumor was driven largely 
by the underlying driver mutation (Fig. 3 and Supplementary Fig. 6). We identified subsets 
of genes and pathways that best characterized each subgroup, and we found that WNT 
signaling and differential expression of key meningeal transcription factors were associated 
with several meningioma drivers (with the use of prediction analysis of microarray19; see 
Online Methods) (Fig. 3a,c and Supplementary Table 10).
We next correlated the gene expression patterns with active super-enhancers, which are 
broad genomic regions that harbor dense clustering of histone 3 lysine 27 acetylation 
(H3K27ac) signals20, 21, 22. We identified 31 super-enhancers with concordant changes in 
gene expression that were more active in all meningioma subgroups (n = 20 in total) as 
compared to dura (n = 2), including the transcriptional regulators FOXP1, FOXP4, HDAC4, 
and KLF2 (Supplementary Table 11 and Supplementary Fig. 7).
We also identified meningioma subtype-specific super-enhancers (Fig. 4 and Supplementary 
Table 12). In the POLR2A subgroup, a super-enhancer covering the WNT6 and WNT10A 
(wingless-type MMTV integration site family, members 6 and 10A) gene locus was 
differentially activated relative to other groups (false discovery rate (FDR) = 1.32 × 10−3; 
log2(fold change) = 1.58), with WNT6 also being significantly overexpressed (FDR = 1.97 × 
10−11; log2(fold change) = 2.00) (Fig. 4b,e). In contrast, a super-enhancer encompassing 
ZIC1 (Zic family member 1), a known meningeal identity gene2, and ZIC4 (Zic family 
member 4) was lost in POLR2A-mutant meningiomas (FDR = 5.45 × 10−3; log2(fold 
change) = −1.72), and both genes were significantly downregulated (Fig. 4b,f) (FDR = 6.49 
× 10−5 and 3.92 × 10−8, respectively; log2(fold change) = −0.44 and −0.92, respectively). 
These results are informative in light of the known roles of WNT and ZIC signaling in the 
growth and differentiation of meningeal progenitors2, 3 (Fig. 4g).
Similarly, in the NF2/SMARCB1 mutant subgroup, the BCL2 (B cell CLL/lymphoma 2) 
oncogene and the developmentally important WNT-signaling regulators DAAM2 
(dishevelled associated activator of morphogenesis 2), NKD1 (naked cuticle homolog 1), 
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FZD4 (frizzled class receptor 4), and SFRP2 (secreted frizzled-related protein 2) were 
expressed in significantly higher amounts and had more highly bound super-enhancers (Fig. 
4c, Supplementary Fig. 8, and Supplementary Table 13).
For the KLF4/TRAF7 subgroup, given that wild-type KLF4 has a role in super-enhancer 
formation in embryonic stem cells20, we hypothesized that mutant KLF4 might directly alter 
super-enhancer binding. Indeed, we found that the KLF4 p.Lys409Gln mutant bound to a 
previously unreported consensus site (Fig. 4h) that was significantly enriched in the KLF4/
TRAF7-group-specific super-enhancers as compared to background (P = 0.001), leading to 
activation of downstream gene expression (Fig. 4i). The developmentally important 
transcription-factor-encoding gene GRHL3 (grainyhead-like 3 (Drosophila)), which is 
fundamental in neural tube development23 (FDR = 1.37 × 10−10, log2(fold change) = 1.09), 
had higher super-enhancer binding and expression in KLF4/TRAF7 co-mutant tumors 
compared with the other four meningioma subgroups (Fig. 4d and Supplementary Fig. 8).
Comprehensive genomic analysis of benign meningioma has yielded fascinating insights 
about the biology of this disease. We have discovered a precarious balance that exists in 
fundamental transcriptional machinery, whereby a single mutation can transform 
physiologic activity into a driver of neoplasia. Using gene expression and super-enhancer 
analysis, we found that alterations in POLR2A result in dysregulation of key identity genes 
in meningeal development2, 3. Indeed, a pan-analysis of meningioma drivers showed 
recurrent involvement of embryonic signaling mechanisms that are fundamental to formation 
of the meninges. This interesting finding raises the possibility that benign meningioma may 
arise from early progenitor cells as a result of developmental dysregulation or, alternatively, 
induced dedifferentiation of mature cells into a stem-like state. Further experiments are 
needed to answer these questions.
Methods
Clinical materials
Institutional review board approvals for genetic studies, along with written consent from all 
study subjects, were obtained at the participating institutions. Formal pathology reports 
along with pre-operative magnetic resonance imaging studies were collected from 
participants.
Selective tissue dissection
For each frozen specimen submitted for whole-exome sequencing, sections were re-
reviewed to confirm the diagnosis and assess the adequacy of the frozen tissue for 
experimental analysis. On hematoxylin-and-eosin-stained sections from frozen tissue blocks, 
areas of interest were identified and microscopically dissected to ensure that each sample 
consisted of >70% tumor cells; unwanted regions such as inflammatory and necrotic areas 
were excluded. Tumors in the replication cohorts did not undergo selective tissue dissection. 
DNA/RNA was prepared using the All prep DNA/RNA mini kit (Qiagen, 80004) with the 
assistance of a QIAcube (Qiagen, 9001292).
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Whole-genome genotyping
The Illumina platform was used for whole-genome genotyping and analysis of the samples 
(n = 94). Human OmniExpress-12v1.0 BeadChips containing 733,202 markers were used 
according to the manufacturer’s protocol (Illumina, WG-315-1101). All samples had an 
overall genotype call rate greater than 98%. We detected copy-number alterations by 
comparing the normalized signal intensity between tumor and matched blood or tumor and 
the average of all blood samples. Segmentation was performed on log intensity (R) ratios 
using the DNA Copy algorithm26. Large-scale chromosomal deletion or amplification was 
defined as affecting more than one-third of the chromosomal arm with an accompanying log 
ratio of signal intensities < −0.1 or > 0.1 and B allele frequencies at heterozygous sites 
deviating from 0.5 by at least 0.05 units. Large-scale copy-neutral loss of heterozygosity was 
defined similarly, with the exception of the log ratio of signal intensities being between −0.1 
and 0.1.
Exome capture and sequencing
Nimblegen/Roche human solution-capture exome array (Roche NimbleGen, 05860504001) 
was used to capture the exomes of blood and tumor samples according to the manufacturer’s 
protocol with modifications27. We sequenced the library on Illumina HiSeq instruments 
using paired-end 74-bp reads by multiplexing two tumor samples or three blood samples per 
lane.
Exome sequence analysis
We analyzed sequence reads that passed the Illumina quality filter. Before alignment, we 
trimmed the low-quality 3′ end of the reads and filtered reads with low-complexity 
sequences and overall low base qualities (FASTX-Toolkit). We trimmed PCR primer-
contaminated sequence segments (cutadapt version 0.9.5) and kept sequences for further 
analysis only if both reads in a pair had more than 35 bases remaining after the above 
trimming and filtering quality measures. We aligned reads to the human genome reference 
sequence (version GRCh37, the same as used in phase 1 of the 1000 Genomes Project) using 
Stampy (version 1.0.16)28 in a hybrid mode with BWA (version 0.5.9-r16)29. PCR 
duplicates were flagged using the MarkDuplicates algorithm from Picard and excluded from 
further analysis as previously described30. Metrics describing the alignment quality, such as 
the fraction of unique read pairs, the fraction of aligned reads, and depth of coverage, were 
collected for each sample with the CollectAlignmentSummaryMetrics and 
CalculateHsMetrics utilities of Picard (Supplementary Table 14). We performed multi-
sequence local realignment around putative and known insertion/deletion (indel) sites, where 
the reads from tumor and matched blood samples were analyzed at the same time. This was 
followed by the base quality score recalibration using the Genome Analysis Toolkit (GATK, 
version 1.5–20)30. We detected variant sites (point mutations and small indels) for tumor and 
matched blood pairs using the UnifiedGenotyper algorithm from GATK30. Variants were 
concurrently called for unpaired tumor samples using UnifiedGenotyper. To identify somatic 
events, we used a genotype-likelihood-based somatic score proposed by Li31. We used the 
same phred-scaled score as implemented in bcf tools32. We considered a mutation to be 
somatic if the matched blood sample was homozygous reference while the tumor sample 
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was heterozygous non-reference and if the somatic score was ≥50. We filtered variant sites 
by assessing the allelic and overall depth of coverage, the strand, mapping quality and read 
position biases between reference and non-reference allele supporting reads, the consistency 
between the number of alleles and that of haplotypes, the root mean square of the mapping 
quality, the coverage-adjusted variant quality, and the number of mapping-quality-zero 
reads. For insertions, we used the maximum score of flanking bases, and for deletions, we 
used the maximum score of deleted bases. Finally, we annotated variant alleles using the 
Ensembl database (version 66) with the help of the Variant Effect Predictor (v2.4) tool. From 
these functional annotations, we selected the most deleterious consequence for each variant 
site and considered the variant allele to be deleterious if its consequence was annotated as 
stop gained, complex change in transcript, frameshift, splice acceptor/donor sites, stop lost, 
non synonymous codon predicted to be deleterious/damaging, or in-frame codon loss/gain. 
We initially considered genes that were mutated in more than one tumor and prioritized 
genes on the basis of the ratio of deleterious to non-deleterious mutations observed. The co-
occurrence and mutual exclusivity of genes were assessed using one-sided Fisher’s exact 
test33. To leverage whole-exome sequencing data to detect large-scale chromosomal 
amplifications or deletions, we used the exomeCNV algorithm34.
Whole-genome sequencing and breakpoint analysis
After quality control and quantification of genomic DNA, whole-genome sequencing 
libraries were prepared using the Illumina TruSeq DNA PCR-Free sample preparation kit 
(Illumina, FC-121-3001) according to the manufacturer’s protocol. Sequencing was 
performed on the Illumina Hiseq 4000 platform using paired-end chemistry at a read length 
of 100 bp. Sequencing reads were processed using GATK Best Practices. Break dancer35 
was used to call breakpoints, with multi-sample calling mode used to assess the somatic 
status of breakpoints. Intrachromosomal breakpoints were filtered if (i) breakpoints were 
less than 200 bp apart, (ii) there were any supporting reads from the matching blood, (iii) 
there were fewer than eight supporting reads in the tumor, or (iv) breakpoints had a quality 
score of <40. Breakpoints were then annotated using ANNOVAR for hg19 refSeq genes, 
cyto-band information, segmental duplications, and repeat masked regions and were 
subsequently filtered if there was overlap with segmental duplications or any repeat 
elements. Breakpoints with >25 reads are shown in Supplementary Table 2. Breakpoints 
with >25 supporting reads were plotted in Circos plots (Supplementary Fig. 1).
Custom molecular inversion probe (MIP) sequencing and analysis
Targeted sequencing of exomic regions and exon–intron boundaries of NF2, SMARCB1, 
TRAF7, PIK3CA, PIK3R1, PRKAR1A, SMO, and SUFU plus the recurrent variants AKT1 
p.Glu17Lys and KLF4 p.Lys409Gln was performed using MIPs. Probes were designed and 
libraries were generated as previously described, with slight modifications36. We carried out 
multiplex capture of targeted sequences using 150 ng of genomic DNA for each sample 
through probe hybridization, gap filling and ligation, and exonuclease digestion. The 
captured DNA was amplified using barcoded primers. Libraries were cleaned up with 
AMPure XP beads (Beckman Coulter, A63880), quantified by picogreen, and pooled with 
80 meningiomas per lane. Pooled libraries were sequenced on the HiSeq 2500 system using 
paired-end 101-bp reads according to the manufacturer’s protocol. Sequence reads were 
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processed like the whole-exome data as described previously, but without duplication 
removal, indel realignment, or base quality recalibration4. Variants were called using 
GATK’s UnifiedGenotyper.
Custom amplicon sequencing and analysis
Libraries consisting of the coding exons from TRAF7, NF2, SMO, and the recurrent 
mutations for AKT1 p.Glu17Lys and KLF4 p.Lys409Gln were created using the TargetRich 
custom amplicon kit (Kailos Genetics). We pooled and sequenced 48 samples on a version 2 
Illumina MiSeq using paired-end 150-bp reads. Sequence reads were processed like the 
whole-exome data, but without duplication removal and base quality recalibration. Variants 
were called for all samples using GATK’s UnifiedGenotyper.
Sanger sequencing
Coding variants detected by whole-exome sequencing or targeted next-generation 
sequencing were confirmed by Sanger sequencing using standard protocols27. In addition to 
whole-exome-sequenced tumors (n = 107), we screened POLR2A exon 7, containing the 
recurrent dock domain mutations, by Sanger sequencing in 452 tumors. Amplicons were 
cycle-sequenced on ABI’s 9800 Fast Thermocyclers and analyzed as previously described4.
Chromosome 22 quantification by qPCR
We assessed chr22 loss by quantitative real-time PCR (qRT-PCR) using Fast SYBR Green 
Master Mix (Thermo Fisher, 438561). For each sample, two exons in NF2 were used for 
quantification and normalized against primers on chromosomes 11 and 16. Samples and 
controls were run in triplicate. Dissociation curves were generated to ensure primer 
specificity. To determine the threshold cycle, we used female reference DNA (Promega, 
G1521), diluted at 22 ng/μl, for four serial dilutions from 1/4-fold to 1/256-fold. Each qPCR 
run was compared to three samples: a commercially available reference female DNA, DNA 
from a whole-genome-genotyped meningioma sample with chr22 loss (MN-290), and DNA 
from a whole-genome-genotyped meningioma sample with intact chr22 (MN-1). We 
considered a ratio of <0.7 as indicative of a loss and a ratio of >1.3 as indicative of a gain.
Structural analysis
Figures were created using PyMOL (The PyMOL Molecular Graphics System, Version 
1.5.0.1, Schrödinger, LLC). We used the following PDB IDs: PDB ID 2WBU for KLF4; 
PDB ID 2OVQ for FBXW7; and PDB ID 1R5U for yeast RPB1. The Clustal Omega 
algorithm was used for alignment of TRAF7 WD40 repeat domains (Fig. 2b).
RNA-seq and analysis
Meningioma mRNA was extracted using the Allprep DNA/RNA Mini Kit. RNA integrity 
number (RIN) was assessed using an Agilent Bioanalyzer 2100, and samples with RIN < 5.7 
were excluded. Ribozero depletion was performed, and samples were loaded four per HiSeq 
2500 lane (paired-end, 75-bp sequencing). RNA-seq reads passing the Illumina quality filter 
underwent read pre-processing as described in the section “Exome sequence analysis” and 
were analyzed using the Tuxedo suite of tools37, 38. Briefly, reads were aligned using 
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TopHat2, transcripts were assembled using Cufflinks, a merged assembly file was created 
using Cuffmerge, abundance calculations were carried out using Cuffquant, differential 
expression was analyzed using Cuffdiff, and CummeRbund was used to visualize the 
Cuffdiff output. To visualize RNA-seq reads spanning TRAF7 intron 10, we visualized 
aligned BAM files using the Integrative Genomics Viewer39.
Microarray data analysis
We used the Illumina HumanHT12.v4 BeadChip array (Illumina, BD-103-0204) on samples 
collected from ten different batches. Data were normalized using normal–exponential 
convolution model–based background correction and quantile normalization using the limma 
R package40. We normalized all the batches at once after excluding probes with low quality. 
Samples estimated to have a zero proportion of expressed probes, mean signal intensity less 
than 5.54 or an RIN value less than 3, were excluded. Hierarchical clustering of the gene 
expression data showed batch and chip effects in the data. The batch and chip effects were 
removed using ComBat in sva R package41. We performed unsupervised hierarchical 
clustering based on a Euclidean distance metric and average linking clustering on the probes. 
Differentially expressed genes were identified using an empirical Bayesian method, ebayes, 
implemented in limma. A log-odds score of 2 and an absolute log fold change of 1 were 
used to define the threshold. MicroRNA was not analyzed.
CRISPR–Cas9 gene editing of v6.5 mouse embryonic stem cells
To model the POLR2A missense mutations, we established 20-nt CRISPR guide sequences 
with BbsI overhang. For creation of the repair template, gBlocks (Integrated DNA 
Technologies) were designed to carry the desired mutation with 750 bp of flanking wild-type 
genomic sequence plus the addition of restriction sites (SacI and SphI) to the ends of the 
gBlocks. To perform targeted gene editing, we transiently transfected v6.5 mouse embryonic 
stem cells (mESCs) using Xfect; GFP+ cells were sorted by flow cytometry at 26 h post-
transfection, and individual colonies were picked, trypsinized, cultured, and sequenced to 
confirm successful generation of a knock-in genotype. POLR2A dock domain mutations 
were validated by Sanger sequencing.
FPKM calculation of RNA-seq data from POLR2A mutant and wild-type v6.5 mESCs
RNA was extracted from an equal number of cells harvested in triplicate from three 
independent cell lines: two independent POLR2AQ403K lines (A7 and B10) generated by 
CRISPR–Cas9 gene editing, and wild-type v6.5 mESCs42. Briefly, total RNA was purified 
from equal numbers of cells using the mirVANA miRNA isolation kit (Ambion, AM1560), 
spiked in with External RNA Controls Consortium ExFold Mix #1 RNA spike-in controls, 
digested with DNA-free DNase I, and processed for RNA-seq as described above. The 
RNA-seq data were analyzed as described above; then the FPKM (fragments per kilobase of 
transcript per million mapped reads) values were re-normalized using the spike-in controls 
with a LOESS regression. Transcripts with an FPKM value of 1 or greater in wild-type cells 
were selected, and the density of transcripts with a given FPKM value was plotted.
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Meningioma gene expression subgroups
‘Partitioning around medoids’ clustering was performed on the top 1,000 most variably 
expressed genes to identify robust meningioma clusters, using the ‘pam’ function of the 
‘cluster’ package in R. Sample silhouette widths were also calculated using the ‘silhouette’ 
function. To determine the optimal number of gene expression clusters, clustering was 
repeated for 2–15 total clusters. When five clusters were formed, the mean sample silhouette 
width was the highest, and therefore we chose this number of clusters for downstream 
analysis. To identify the ‘core’ samples of each cluster, we further excluded samples with 
negative silhouette widths, retaining 79 tumor samples43, 44, 45. In addition, Fisher’s exact 
tests were used to test the associations between gene expression clusters and mutational 
profiles. Cluster names were determined accordingly. Lastly, to assess clustering robustness, 
we used four additional clustering methods on the same set of 79 samples, including 
consensus clustering (ConsensusClusterPlus package), non-negative matrix factorization 
(NMF package), hierarchical clustering (cluster package), and principal component analysis 
(cmdscale function)46, 47. All five clustering algorithms consistently identified the five 
meningioma subgroups.
Meningioma signature gene identification
First, we carried out significance analysis of microarray to identify significantly 
differentially expressed genes among the five meningioma subgroups, using the samr 
package in R44, 45, 48. Second, we carried out prediction analysis of microarray (PAM) to 
discover gene signatures specific to each of the meningioma subgroups, using the pamr 
package in R19, 44, 45, 49. The PAM scores reflected positive or negative correlations between 
gene expression and each subgroup19. A total of 5,641 signature genes were selected 
(median FDR = 0.0042; 95th percentile FDR = 0.013). In addition, each signature gene was 
assigned to the subgroup with the highest absolute PAM score. Lastly, functional enrichment 
of subgroup-specific genes was performed using DAVID50.
H3K27ac ChIP-seq
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) was performed as 
previously described, with minor adjustments51. H3K27ac ChIP and input samples were 
sequenced for each tumor (1 × 75 bp, HiSeq 2000). Reads were aligned uniquely with 
Bowtie (0.12.7)52 to the human genome (hg19), and regions of enrichment were identified 
with MACS (v1.4).
Meningioma super-enhancer analysis
H3K27ac ChIP and input samples were sequenced for each tumor (1 × 75 bp, HiSeq 2000). 
Reads were aligned uniquely with Bowtie (0.12.7)52 to the human genome (hg19), and 
regions of enrichment were identified with MACS (v1.4)53. We filtered reads by removing 
those that contacted RNA repeats from RepeatMasker by at least 1 bp using BEDtools. 
Super-enhancers were identified as described by Chipumoro et al.54 using these reads. 
Super-enhancers were separated from typical enhancers using ROSE2 with parameters -s 
(stitching) 12500, -t (promoter exclusion zone) 2000. We used DiffBind to estimate the 
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significance of super-enhancer read changes (adjusted P value threshold = 0.05) between 
meningioma subtypes55 (Supplementary Table 12).
Super-enhancer and gene expression concordance analyses
We undertook several complementary approaches to calculate super-enhancer and gene 
expression concordance. We initially considered the union of super-enhancers from all 
meningioma and dura samples, merging overlapping super-enhancer regions and thereby 
creating consensus super-enhancer sets. We then identified super-enhancers common to all 
meningioma subgroups. To detect meningioma-specific super-enhancers, we excluded super-
enhancers that were present in all dura samples. Super-enhancer regions were annotated 
using the GREAT Annotation tool. Finally, we evaluated the concordance between super-
enhancers and gene expression changes. We identified meningioma-specific super-enhancer-
driven genes as those with meningioma-specific super-enhancers and increased expression in 
meningiomas as compared with dura samples (differential expression log-odds score > 2) 
(Supplementary Table 11).
In parallel (Supplementary Table 13), for each meningioma subgroup or dura sample, 
overlapping super-enhancers were merged. Super-enhancers identified in at least two 
samples of the same subgroup were regarded as a ‘consensus’ subset and were retained for 
subsequent analysis. In addition, consensus super-enhancers in meningiomas that overlapped 
with those of dura were excluded, leaving a set of meningioma-specific super-enhancers. 
Subgroup-specific super-enhancers were further identified using the same approach as 
described above.
KLF4 ChIP
Lipofectamine 2000 was used to transfect 293T cells with wild-type KLF4, mutant KLF4, or 
empty vector, according to standard manufacturer protocols. At 48 h post-transfection, the 
cells were harvested for ChIP. Briefly, 5 × 107 cells were cross-linked with 1% 
formaldehyde, treated with glycine to halt fixation, and washed with PBS. Nuclei were 
harvested and resuspended in nuclear lysis buffer containing 0.1% SDS. Chromatin was 
sheared by sonication with a Bioruptor Standard sonication device with a 1.5-ml tube holder 
(30 min total, 30 s pulses, 30 s rest). Soluble chromatin was incubated with protein G 
Dynabeads (100 μl) coated with 10 μg of anti-KLF4 (AF3640, R&D Systems) overnight at 
4 °C. To control for enrichment, we held back 10% of the chromatin for input. The 
chromatin was precipitated magnetically, washed, and eluted from the antibody-coated 
beads. Cross-links were reversed by overnight incubation at 65 °C, after which the DNA was 
purified and quantified using PicoGreen. Enrichment was verified by ChIP-qPCR using 
relative (ΔΔCt) quantification. Libraries were prepared for next-generation sequencing on 
the Illumina platform and sequenced (1 × 75 bp, HiSeq 2500).
KLF4 ChIP-seq data analysis
For ChIP-seq data analysis, Cutadapt was used to remove sequencing adaptors, FASTX-
Toolkit was used for read quality trimming, bowtie1 using the m = 1 option was used to 
align uniquely mapping reads, PICARD was used to mark and remove PCR duplicates, SPP/
PhantomPeakQualTools was used for cross-correlation analysis, MACS2 was used for peak 
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calling, GREAT was used for peak annotation, and MEME-ChIP was used for motif 
analysis.
Enrichment of novel motif in KLF4-specific super-enhancer active genes
We first searched the novel KLF4 consensus motif against the human genome (hg19) using 
the TOMTOM tool56. Then we generated the background KLF4 consensus motif regions 
based on n = 1,000 permutations. We recalculated the overlapping regions between the 
permuted regions and KLF4-specific super-enhancer active genes. The permutation P value 
was calculated as the proportion of overlapping regions that was more than what we 
observed. We also performed a similar permutation test to assess the enrichment between the 
KLF4 consensus motif regions and other group-specific active super-enhancers.
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Figure 1. POLR2A mutations define a distinct subset of benign meningiomas
(a) The recurrent somatic POLR2A mutations localize to the highly conserved dock domain, 
where interactions with TFIIB mediate the formation of the pre-initiation complex. 
Alterations found in human meningioma were mapped to the Saccharomyces cerevisiae 
RPB1 structure (PDB ID 1R5U). Green, RPB1 p.Gln403Lys equivalent residue; teal, RPB1 
p.Leu438_His439del equivalent residues; yellow, zinc ion. (b) Alignment of the protein 
sequences of the large Pol II subunit for seven species shows the dock domain, including the 
two residues altered by recurrent meningioma mutations, to be highly conserved. (c.d) 
Representative Sanger chromatograms of recurrent POLR2A mutations in tumor and 
matching blood show that the mutations are somatic. Mutant alleles are confirmed by RNA-
seq reads. gDNA, genomic DNA. (e) A representative Circos plot of a whole-genome-
sequenced POLR2A meningioma does not show any large-scale chromosomal 
rearrangements. (f) The percentage of the genome altered by copy-number variations 
between meningioma subgroups. The low proportion of the genome altered by copy-number 
variation was similar in POLR2A mutant tumors and other non-NF2 mutant meningiomas. 
(g) The number of somatic mutations (normalized per megabase pair of sequencing data) 
from whole-exome sequencing data that are protein-altering and predicted to be damaging. 
In f and g, lines indicate median values, box edges indicate 25th (bottom) and 75th (top) 
percentiles, and whiskers and points show the outliers. (h) POLR2A meningiomas are 
enriched along the skull base, near the tuberculum sellae region (highlighted in pink).
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Figure 2. Meningioma driver genes in five major pathways account for the formation of >80% of 
benign meningiomas
(a) The distribution of the 182 TRAF7 mutations showed highly recurrent missense 
mutations that clustered in the WD40 repeat domains or mutations affecting the splice 
junction immediately upstream of the WD40 repeat domain (n = 12), but not frameshift or 
nonsense mutations. Del, deletion; ins, insertion; aa, ammo acid. (b) Alignment of TRAF7 
WD40 repeats. Left: the previously reported R1–2, R1, and D1 WD40 mutation hot spots24. 
Boxes A, B. C, and D identify recurrent structural motifs shared by WD40 repeat domains. 
Blue-shaded amino acids mark mutations detected in meningioma, whereas red-shaded 
amino acids represent highly recurrent meningioma mutations (seen in more than ten 
tumors). Right: typical WD40 repeat (here, FBW7 WD40 repeat 3, PDB ID 2QVQ) with 
color-coded structural motifs and hot-spot mutations. (c) Recurrent TRAF7 splice mutations 
promote intron inclusion, resulting in a 28-amino-acid in-frame insertion plus a Ser-to-Cys 
missense alteration. (d) Distribution of PIK3CA mutants showing hot spots at p.Glu545 and 
p.His1047, which have been previously reported to result in constitutive PI3K signaling8, 25. 
(e) Distribution of the driver genes detected in the benign (WHO grade I) meningioma 
cohort. Each bar represents a meningioma sample. Only genes screened via targeted next-
generation sequencing and/or Sanger sequencing are plotted. Our analysis identified somatic 
mutations in POLR2A, PIK3R1, SUFU, and PRKAR1A that were mutually exclusive with 
the previously identified meningioma genes. (f) Benign meningiomas form mutually 
exclusive subgroups based on mutational background.
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Figure 3. Meningioma subgroups cluster according to their genome-wide transcription profile 
and show significant differences in the expression of critical developmental regulators
(a) Unsupervised hierarchical clustering of gene expression in meningioma tumor samples. 
The width of each clustering silhouette is a measure of the tumor’s match within the 
indicated subgroup. Each point represents a single tumor. (b) The number of clusters used 
for analysis was chosen to maximize the mean width of the clustering silhouette. Clustering 
with five subgroups gave optimal results. (c) Subgroup-specific genes were selected for heat-
map generation in a supervised approach via a classification algorithm. For each subgroup, 
representative genes and the pathways they belong to are presented on the right. Upregulated 
genes are shown in red, and downregulated ones in blue. Pathway enrichment was performed 
using a hypergeometric test: *P < 0.05, **q <0.1. (d) Samples clustered according to 
underlying driver mutation, q-values were calculated via two-sided Fisher’s exact test.
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Figure 4. Super-enhancer-driven genes classify meningioma subgroups
(a) Unsupervised hierarchical clustering based on super-enhancer binding classifies 
meningioma subgroups. Super-enhancer binding scores were derived from affinity based on 
H3K27ac ChIP-seq read counts. (b–d) Concordant differential gene expression and 
differentially bound super-enhancers between meningioma subgroups. Red points represent 
a differentially high-binding super-enhancer (FDR < 0.05) with concordant upregulation of 
its nearby target gene (FDR < 0.05). Blue points represent a differentially low-binding 
super-enhancer that correlates with downregulation of its target gene. (e,f) Differential 
super-enhancer binding and gene expression was detected at the WNT6/WNT10A (e) and 
ZIC1/ZIC4 (f) loci in POLR2A mutant tumors compared with other meningioma subgroups 
and control dura (‘normal’). Background shading represents super-enhancers present in two 
or more samples per subtype. Expression is log2 transformed, rpkm, reads per kilobase of 
transcript per million mapped reads. (g) Schematic outlining the roles of WNT6 and ZIC1 in 
controlling neural crest development and meningeal cell differentiation. During embryonic 
development, WNT6 is expressed and secreted by the non-neural ectoderm (purple) to 
Clark et al. Page 19
Nat Genet. Author manuscript; available in PMC 2016 November 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
trigger induction of neural crest cells (light blue), whereas ZIC1 is expressed by neural crest 
cells and is a marker for meningeal cells. (h) Compared to the wild-type KLF4 consensus 
binding sequence, the two 3′-most nucleotides of the KLF4 p.Lys409Gln mutant consensus 
DNA binding sequence were altered to T and G, respectively. (i) Using luciferase assays, we 
confirmed that KLF4 p.Lys409Gln binds to this novel mutant motif in vitro, activating 
higher downstream gene expression than either the control or wild-type KLF4. Error bars 
represent s.d., calculated over three replicates.
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